Fig 1: Mifepristone reduces the secretion of IL-6 and TNF-a from endometrial epithelial and stromal cells in adenomyosis. (A) Human primary endometrial epithelial cells were treated with mifepristone in different concentrations for 24h, and CCK-8 assay was performed. The viability of endometrial epithelial cells was significantly decreased when treated with mifepristone at 75 µM while there was no significant difference at 50 µM. Concentration at 50 µM was therefore selected for the following RNA-sequencing. (B) Primary endometrial epithelial cells were treated with mifepristone at the concentration of 50 µM and then subjected to next generation sequencing. The endometrial epithelial cells were from four biologically independent samples and the data were shown in quadruplicate. (C) qRT-PCR and ELISA were performed to detect the role of mifepristone on the down-regulations of IL-6 and TNF-a in endometrial epithelial and stromal cells in different concentrations. Data were shown as mean ± SEM. *P<0.05, **P<0.01 and ***P<0.001.
Fig 2: TRPV1 ion channel current is attenuated by LPS and by interleukin-6 (IL-6). (a) I–V curves of the capsazepine-sensitive TRPV1 current in absence (control, Ctr, circles) and presence of LPS or IL-6 (LPS, 1 µg/mL, 6 h: squares, IL-6, 10 ng/mL, 6 h: triangles). Vm—membrane potential. (b) Mean values of the capsazepine-sensitive TRPV1 current at - 70 mV in absence (control, Ctr) and presence of LPS or IL-6 (LPS, 1 µg/mL, 6 h. IL-6, 10 ng/mL, 6 h). *p < 0.05. Data of two independent experiments are shown. Unstimulated control cells, n = 8; n = 4 biological replicates per experiment. LPS, n = 8; n = 4 biological replicates per experiment. IL-6, n = 10; n = 5 biological replicates per experiment.
Supplier Page from RayBiotech for Human IL-6 ELISA